Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells

Cancer Research

Volumn 68, Issue 18, 2008, Pages 7512-7519

  Mankaï, Amani ^a   Bordron, Anne ^a   Renaudineau, Yves ^a   Martins Carvalho, Christine ^a   Takahashi, Shinichiro ^b   Ghedira, Ibtissem ^c   Berthou, Christian ^a   Youinou, Pierre ^a,d  

^a Medical School   (France)

^b University Graduate School of Medical Science   (Japan)

^c UNIVERSITY OF MONASTIR   (Tunisia)

^d BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD20 ANTIGEN; COMPLEMENTARY DNA; DNA METHYLTRANSFERASE INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOIC ACID; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PU 1;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HUMAN; LYMPHOMA; MALE; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; DNA METHYLATION; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE THERAPY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSFECTION;

EID: 54649084539     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6446     Document Type: Article

References (49)

1. Dameshek W. Chronic lymphocytic leukemia: an accumulative disease of immunological ly-incompetent lymphocytes. Blood 1967;29:566-84.
2. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of CLL B cells. J Clin Invest 2005;115:755-64.
3. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
4. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in CLL. Blood 1999;94:1840-7.
5. Oppezzo P, Vasconcelos Y, Settegrana C, et al. French Cooperative Group on CLL. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005;106:650-7.
6. Renaudineau Y, Nédellec S, Berthou C, Lydyard PM, Youinou P, Pers JO. Role of B-cell antigen receptor-associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells. Leukemia 2005;19:223-9.
7. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51.
8. Pers JO, Berthou C, Porakishvili N, et al. CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. Leukemia 2002;16:44-52.
9. Nédellec S, Renaudineau Y, Bordron A, et al. B cell response to surface IgM cross-linking identifies different prognostic groups of B-chron ic lymphocytic leukemia patients. J Immunol 2005;174:3749-56.
10. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
11. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-31.
12. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-43.
13. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52.
14. Uchida J, Hamaguchi Y, Olivier JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69.
15. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992;40:259-63.
16. van Meerten T, Van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to ADCC. Clin Cancer Res 2006;12:4027-35.
17. Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 1997;90:3984-95.
18. Thevenin C, Lucas BP, Kozlow EJ, Kehrl JH. Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J Biol Chem 1993;268:5949-56.
19. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001;15:557-67.
20. Mueller BU, Pabst T, Fos J, et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 2006;107:3330-8.
21. Hess J, Nielsen PJ, Fischer KD, Bujard H, Wirth T. The B lymphocyte-specific coactivator BOB.1/OBF.1 is required at multiple stages of B-cell development. Mol Cell Biol 2001;21:1531-9.
22. Lyman SD, James L, Zappone J, Sleath PR, Beckmann MP, Bird T. Characterization of the protein encoded by the Flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene 1993;8:815-22.
23. Inomata M, Takahashi S, Harigae H, Kameoka J, Kaku M, Sasaki T. Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias. Leuk Res 2006;30:659-64.
24. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
25. Wahlfors J, Hiltunen H, Heinonen K, Hamalainen E, Alhonen L, Janne J. Genomic hypomethylation in human CLL. Blood 1992;80:2074-80.
26. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-5.
27. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
28. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD. Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med 1994; 180:329-39.
29. Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression. Blood 2004;103:1883-90.
30. Re D, Muschen M, Ahmadi T, et al. Oct2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res 2001;61:2080-4.
31. Ushmorov A, Leithauser F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006;107:2493-500.
32. Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 1990; 61:113-24.
33. Ying H, Chang JF, Parnes JR. PU.1/Spi-1 is essential for the B cell-specific activity of the mouse CD72 promoter. J Immunol 1998;160:2287-96.
34. Ye M, Ermakova O, Graf T. PU.1 is not strictly required for B cell development and its absence induces a B-2 to B-1 cell switch. J Exp Med 2005;202:1411-22.
35. Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000;60:7170-6.
36. Nutt SL, Metcalf D, D'Amico A, Polli M, Wu L. Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J Exp Med 2005;201:221-31.
37. Brasel K, Escobar S, Anderberg R, de Vries P, Gruss HJ, Lyman SD. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia 1995;9:1212-8.
38. Takahashi S, McConnell MJ, Harigae H, et al. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood 2004;103:4650-8.
39. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383-9.
40. Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell CLL. Leuk Lymphoma 2002;43:149-51.
41. Yagci M, Akar I, Sucak GT, Haznedar R. GM-CSF does not increase CD20 antigen expression on CLL lymphocytes. Leuk Res 2005;2:735-8.
42. Chen H, Zhang P, Radomska HS, Hetherington CJ, Zhang DE, Tenen DG. Octamer binding factors and their coactivator can activate the murine PU.1 promoter. J Biol Chem 1996;271:15743-52.
43. Molica S, Levato D, Dattilo A, Mannella A. Clinicoprognostic relevance of quantitative immunophenotyping in B-cell CLL with emphasis on the expression of CD20 antigen and surface immunoglobulins. Eur J Haematol 1998;60:47-52.
44. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and CLL cells by THP-1 monocytes. J Immunol 2006;176:2600-9.
45. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177:7435-43.
46. Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 2000;79:157-73.
47. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-26.
48. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lym phocyte stimulator by B CLL cells: a mechanism for survival. Blood 2002;100:2973-9.
49. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007;179:3351-61.